诚信认证：
工商注册信息已核实！
ZM 306416
| 品牌 | 厂商性质 | 产地 | 货期 |
|---|---|---|---|
| 阿拉丁 | 生产商 | 上海 | 现货 |
| 货号 | CAS号 | 操作 |
|---|---|---|
| Z129748-10mg | 690206-97-4 | 询价 |
| Z129748-50mg | 690206-97-4 | 询价 |
- 分子式 C16H13ClFN3O2
- 分子量333.74
属性
| 溶解性 | DMSO:3 mg/mL; ethanol:1 mg/mL, DMSO:3 mg/mL; ethanol:1 mg/mL |
| 存贮条件 | 储存温度-20°C |
描述
| 产品介绍 | ZM-306416(CB 676475)是VEGFR选择性抑制剂（IC50为670nM），对于Flk-1(KDR)和Flt的IC50分别为100nM和2μM。 |
| 备注 | ZM 306416 is a VEGFR (Flt and KDR) inhibitor for VEGFR1 with IC50 of 0.33 μM, but also found to inhibit EGFR with IC50 of <10 nM. |
| 生化机理 |
Description: IC50 Value: 0.67uM(for VEGFR); 0.33±0.08uM(for Src); 1.3±0.2 μM(for Abl) ZM-306416, a vascular endothelial growth factor receptor (VEGFR) antagonist, was identified as a potent inhibitor of EGFR function [2]. in vitro: 306416 was found to be very potent toward the EGFR kinase with an IC50 value lower than 10 nM, reaching our assay detection limit and confirming our result using the EGFRB assay. ZM-306416 exhibited inhibitory activity across all three kinases of the panel, yielding IC50 values of 0.33±0.08 μM for SRC, 0.33±0.04 μM for VEGFR1, and 1.3±0.2 μM for ABL kinases [1]. in vivo: N/A Clinical trial: N/A |
| 别名 | 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-6,7-dimethoxy-;4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-6,7-dimethoxy- |
ZM 306416信息由上海阿拉丁生化科技股份有限公司为您提供，如您想了解更多关于ZM 306416报价、型号、参数等信息，欢迎来电或留言咨询。
注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途